Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
This approval is a significant achievement in expanding the availability of this critical therapeutic,
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
